REFERENCES
- Rockey DC, Bell PD, Hill JA. Fibrosis-a common pathway to organ injury
and failure. N Engl J Med 2015;372:1138-1149.
- Bataller R, Brenner DA. Liver fibrosis. J Clin Invest
2005;115:209-218.
- Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval
F. The burden of liver disease in Europe: A review of available
epidemiological data. J Hepatol 2013;58:593-608.
- Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al.
Fate tracing reveals hepatic stellate cells as dominant contributors
to liver fibrosis independent of its aetiology. Nat Commun
2013;4:2823.
- Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, et al.
Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad
Sci USA 2014;111:E3297-E3305.
- Kisseleva T. The origin of fibrogenic myofibroblasts in fibrotic
liver. Hepatology 2017;65:1039-1043.
- de Lecea L, Criado JR, Prospero-Garcia O, Gautvik KM, Schweitzer P,
Danielson PE, et al. A cortical neuropeptide with neuronal depressant
and sleep-modulating properties. Nature 1996;381:242-245.
- Gonzalez-Rey E, Delgado M. Emergence of cortistatin as a new
immunomodulatory factor with therapeutic potential in immune
disorders. Mol Cell Endocrinol 2008;286:135-40.
- Gonzalez-Rey E, Chorny A, Robledo G, Delgado M. Cortistatin, a new
antiinflammatory peptide with therapeutic effect on lethal
endotoxemia. J Exp Med 2006;203:563-571.
- Delgado-Maroto V, Falo CP, Forte-Lago I, Adan N, Morell M,
Maganto-Garcia E, et al. The neuropeptide cortistatin attenuates
experimental autoimmune myocarditis via inhibition of cardiomyogenic T
cell-driven inflammatory responses. Br J Pharmacol 2017;174:267-280.
- Gonzalez-Rey E, Chorny A, Del Moral RG, Varela N, Delgado M.
Therapeutic effect of cortistatin on experimental arthritis by
downregulating inflammatory and Th1 responses. Ann Rheum Dis
2007;66:582-588.
- Gonzalez-Rey E, Varela N, Sheibanie AF, Chorny A, Ganea D, Delgado M.
Cortistatin, an antiinflammatory peptide with therapeutic action in
inflammatory bowel disease. Proc Natl Acad Sci USA 2006;103:4228-4233.
- Tracy TF, Tector AJ, Goerke ME, Kitchen S, Lagunoff D. Somatostatin
analogue (Octreotide) inhibits bile duct epithelial cell proliferation
and fibrosis after extrahepatic biliary obstruction. Am J Pathol
1993;143:1574-1578.
- Moreno M, Chaves JF, Sancho-Bru P, Ramalho F, Ramalho LN, Mansego ML,
et al. Ghrelin attenuates hepatocellular injury and liver fibrogenesis
in rodents and influences fibrosis progression in humans. Hepatology
2010;51:974-985.
- Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Rotkvic I, et
al. Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on
liver lesions induced by either restraint stress or bile duct and
hepatic artery ligation or CCl4 administration. A comparative study
with dopamine agonists and somatostatin. Life Sci 1993;53:PL291-PL296.
- Reynaert H, Vaeyens F, Qin H, Hellemans K, Chatterjee N, Winand D, et
al. Somatostatin suppresses endothelin-1-induced rat hepatic stellate
cell contraction via somatostatin receptor subtype 1. Gastroenterology
2001;121:915-930.
- Fort J, Oberti F, Pilette C, Veal N, Gallois Y, Douay O, et al.
Antifibrotic and hemodynamic effects of the early and chronic
administration of octreotide in two models of liver fibrosis in rats.
Hepatology 1998;28:1525-1531.
- Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage
P, et al. Expression of somatostatin receptors in normal and cirrhotic
human liver and in hepatocellular carcinoma. Gut 2004;53:1180-1189.
- Reynaert H, Rombouts K, Jia Y, Urbain D, Chatterjee N, Uyama N, et al.
Somatostatin at nanomolar concentration reduces collagen I and III
synthesis by, but not proliferation of activated rat hepatic stellate
cells. Br J Pharmacol 2005;146:77-88.
- Borie R, Fabre A, Prost F, Marchal-Somme J, Lebtahi R, Marchand-Adam
S, et al. Activation of somatostatin receptors attenuates pulmonary
fibrosis. Thorax 2008;63:251-258.
- Duran-Prado M, Morell M, Delgado-Maroto V, Castaño JP,
Aneiros-Fernandez J, De Lecea L, et al. Cortistatin inhibits migration
and proliferation of human vascular smooth muscle cells and decreases
neointimal formation on carotid artery ligation. Circ Res
2013;112:1444-1455.
- Morell M, Camprubí-Robles M, Culler MD, de Lecea L, Delgado M.
Cortistatin attenuates inflammatory pain via spinal and peripheral
actions. Neurobiol Dis 2014;63:141-154.
- Liu Y, Lin F, Fu Y, Chen W, Liu W, Chi J, et al. Cortistatin inhibits
arterial calcification in rats via GSK3β/β-catenin and protein kinase
C signalling but not c-Jun N-terminal kinase signalling. Acta Physiol
(Oxf) 2018;223:e13055.
- Wang M, Gong Q, Zhang J, Chen L, Zhang Z, Lu L, et al.
Characterization of gene expression profiles in HBV-related liver
fibrosis patients and identification of ITGBL1 as a key regulator of
fibrogenesis. Sci Rep 2017;7:43446.
- Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, et al. Genes
involved in viral carcinogenesis and tumor initiation in hepatitis C
virus-induced hepatocellular carcinoma. Mol Med 2009;15:85-94.
- Moylan CA, Pang H, Dellinger A, Suzuki A, Garrett ME, Guy CD, et al.
Hepatic gene expression profiles differentiate presymptomatic patients
with mild versus severe nonalcoholic fatty liver disease. Hepatology
2014;59:471-482.
- Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker Met al . The ARRIVE guidelines 2.0: Updated guidelines for
reporting animal research. Br J Pharmacol 2020;177:3617-3624.
- Córdoba-Chacón J, Gahete MD, Pozo-Salas AI, Martinez-Fuentes AJ, De
Lecea L, Gracia-Navarro F, et al. Cortistatin is not a somatostatin
analogue but stimulates prolactin release and inhibits GH and ACTH in
a gender-dependent fashion: potential role of ghrelin. Endocrinology
2011;152:4800-4812.
- Seki E, De Minicis S, Österreicher CH, Kluwe J, Osawa Y, Brenner DA,
et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med
2007;13:1324-1332.
- Reddy GK, Enwemeka CS. A simplified method for the analysis of
hydroxyproline in biological tissues. Clin Biochem 1996;29:225-229.
- Weiskirchen S, Tag CG, Sauer-Lehnen S, Tacke F, Weiskirchen R.
Isolation and culture of primary murine hepatic stellate cells.
Methods Mol Biol 2017;1627:165-191.
- Gautier L, Cope L, Bolstad BM, Irizarry RA. “affy—analysis of
Affymetrix GeneChip data at the probe
level.” Bioinformatics 2004;20:307-315.
- Ishak KG. Chronic hepatitis: morphology and nomenclature. Mod Pathol
1994;7:690-713.
- Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An
appraisal of the histopathological assessment of liver fibrosis. Gut
2006;55:569-578.
- Andres-Leon E, Nunez-Torres R, Rojas AM. miARma-Seq: a comprehensive
tool for miRNA, mRNA and circRNA analysis. Sci Rep 2016;6:25749.
- Nikolayeva O, Robinson MD. edgeR for differential RNA-seq and ChIP-seq
analysis: an application to stem cell biology. Methods Mol Biol
2014;1150:45-79.
- Robinson MD, Oshlack A. A scaling normalization method for
differential expression analysis of RNA-seq data. Genome Biol
2010;11:R25
- Reeb PD, Bramardi SJ, Steibel JP. Assessing dissimilarity measures for
sample-based Hierarchical Clustering of RNA sequencing data using
Plasmode Datasets. PLoS One 2015;10:e0132310.
- Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers
differential expression analyses for RNA-sequencing and microarray
studies. Nucleic Acids Res 2015;43:e47.
- Yu G, Wang L-G, Han Y, He QY. clusterProfiler: an R package for
comparing biological themes among gene clusters. OMICS 2012;16:284.
- Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MAet al. Experimental design and analysis and their reporting II:
updated and simplified guidance for authors and peer reviewers. Br J
Pharmacol 2018;175:987-993.
- Xu L, Huy AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, et al.
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for
analysis of hepatic fibrosis. Gut 2005; 54:142-151.
- Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev
Pathol 2011;6:425-456.
- Hagashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key
target in liver fibrosis. Adv Drug Deliv Rev 2017;121:27-42.
- De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, et al.
Gene expression profiles during hepatic stellate cell activation in
culture and in vivo. Gastroenterology 2007;132:1937-1946.
- Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell
activation. Nat Rev Gastroenterol Hepatol 2017;14:397-411.
- Troeger JS, Mederacke I, Gwak G-Y, Dapito DH, Mu X, Hsu CC, et al.
Deactivation of hepatic stellate cells during liver fibrosis
resolution in mice. Gastroenterology 2012;143:1073-1083.
- Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al.
Myofibroblasts revert to an inactive phenotype during regression of
liver fibrosis. Proc Natl Acad Sci USA 2012;109:9448-9453.
- Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver
fibrosis and its regression. Nat Rev Gastroenterol Hepatol
2021;18:151-166.
- Ibañez-Costa A, Luque RM, Castaño JP. Cortistatin: a new link between
the growth hormone/prolactin axis, stress and metabolism. Growth Horm
IGF Res 2017;33:23-27.
- Jordan VK, Zaveri HP, Scott DA. 1p36 deletion syndrome: An update.
Appl Clin Genet 2015;8:189-200.
- Giordano R, Picu A, Bonelli L, Broglio F, Prodam F, Grottoli S, et al.
The activation of somatostatinergic receptors by either
somatostatin-14 or cortistatin-17 often inhibits ACTH hypersecretion
in patients with Cushing’s disease. Eur J Endocrinol 2007;157:393-398.
- Rol A, Todorovski T, Martin-Malpartida P, Escola A, Gonzalez-Rey E,
Aragon E, et al. Structure-based design of a cortistatin analogue with
immunoregulatory activity in models of inflammatory bowel disease. Nat
Commun 2021;12:1869.